AI制药全线疯涨！全球首个AI癌症疫苗大获成功，这些中国企业值得关注！

TL;DR - Moderna and Merck reported Phase III success for personalized mRNA cancer vaccine intismeran plus Keytruda in high-risk melanoma, meeting recurrence-free and distant-metastasis-free survival endpoints. The milestone highlights AI’s role in selecting patient-specific tumor neoantigens and designing individualized mRNA therapies.

• The trial enrolled more than 1,100 patients and represents the first reported Phase III success for an individualized neoantigen and mRNA-based cancer therapy.
• The workflow sequences tumor and normal samples, then uses a proprietary algorithm to rank mutations and select up to 34 neoantigens for a patient-specific mRNA vaccine.
• AI-driven sequence design and screening can improve mRNA stability, translation, and manufacturability while reducing experimental work.
• Chinese companies including Jitai Technology, XtalPi, Insilico Medicine, Raina Biosciences, and NeoCura are developing AI platforms for mRNA design, delivery, and tumor neoantigen prediction.